美沙拉嗪联合灌肠治疗溃疡性结肠炎的临床研究

The Clinical Research on Treating Ulcerative Colitis by Mesalazine plus Enema

目的分析研究美沙拉嗪口服联合灌肠治疗溃疡性结肠炎的临床疗效。方法将2010年3月至2011年3月期间在我院治疗的68例患者随机分成治疗组和对照组各34例,治疗组口服美沙拉嗪缓释颗粒同时给予美沙拉嗪灌肠剂;对照组给予口服柳氮磺胺吡啶,比较两组的临床疗效及治疗前后肠镜检查肠黏膜变化情况。结果治疗组的总有效率为94.12%,对照组的总有效率为85.29%。两组临床疗效比较差异有统计学意义(uc=-6.854,P<0.05),且治疗组不良反应发生率低于对照组(P<0.05),与治疗前比较,两组肠黏膜的充血水肿、溃疡、糜烂、出血点及瘢痕治疗后均显著减轻(P<0.05),但治疗前、后两组间比较差别均无统计学意义(P>0.05)。结论美沙拉嗪联合灌肠治疗溃疡性结肠炎疗效确切,不良反应发生率低,安全可靠,值得临床推广应用。

Objective To observe the clinical effects on treating ulcerative colitis by mesalazine plus enema on the patients.Methods A retrospective analysis of clinical data was conducted in 68 patients with ulcerative colitis who were admitted in our hospital from march 2010 to march 2011,which were randomly divided into treatment group and control group with 34 patients each.The treatment group was treated with mesalazine plus enema;the control group was treated with Sulfasalazine.The two groups clinical effects and intestine mucous membrane by enteroscopy before and after treatment were observed.Results The total effective rate of treatment group was 94.12% and that of the control group was 85.29%,there were significant differences between the two groups（u=-6.854,P0.05）,the adverse reaction rate in treatment group was lower than the control group（P0.05）.The mucosa hyperemia edema,ulcer,erosion,petechia and cicatricose of two groups had obviously disappearance after treatment（P0.05）,but the differences between two groups before and after treatment were not significant（P0.05）.Conclusion Mesalazine plus enema treating ulcerative colitis patients is proved to be a safe and effective therapy,worthy of clinical promotion.